Gregory Russotti
Technik-/Wissenschafts-/F&E-Leiter bei CENTURY THERAPEUTICS, INC.
Vermögen: 1 Mio $ am 31.05.2024
Profil
Gregory Russotti is currently an Advisor at Dynamk Capital LLC and the Chief Technology & Manufacturing Officer at Century Therapeutics, Inc. He previously worked at Celgene Corp.
as the VP of Cell Therapy Development and Operations from 2013 to 2019.
Dr. Russotti holds a doctorate degree from Rutgers State University of New Jersey, as well as undergraduate and graduate degrees from Rensselaer Polytechnic Institute.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 05.06.2024 | 375 092 ( 0,45% ) | 1 Mio $ | 31.05.2024 |
Aktive Positionen von Gregory Russotti
| Unternehmen | Position | Beginn |
|---|---|---|
| CENTURY THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2020 |
Dynamk Capital LLC
 Dynamk Capital LLC Investment ManagersFinance Dynamk Capital LLC (Dynamk Capital) is a venture capital firm founded in 2017 by Daniella Kranjac and Mario Kranjac. The firm is headquartered in New York, New York. | Berater | - |
Ehemalige bekannte Positionen von Gregory Russotti
| Unternehmen | Position | Ende |
|---|---|---|
| CELGENE | Corporate Officer/Principal | 31.12.2019 |
Ausbildung von Gregory Russotti
| Rensselaer Polytechnic Institute | Graduate Degree |
| Rutgers State University of New Jersey | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CENTURY THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Dynamk Capital LLC
Dynamk Capital LLC Investment ManagersFinance Dynamk Capital LLC (Dynamk Capital) is a venture capital firm founded in 2017 by Daniella Kranjac and Mario Kranjac. The firm is headquartered in New York, New York. | Finance |
